Oncolys BioPharma Inc.
Q2 FY2026 Financial Summary (Interim)
For FY2026 interim period (Q2), revenue was 503,090 thousand yen, operating loss 767,606 thousand yen, ordinary loss 760,604 thousand yen, and interim net loss 762,153 thousand yen. Compared with the same period prior year, revenue increased to 28,546 thousand yen, and net loss narrowed. In regulatory matters, OBP-301 price approval and listing are proceeding. There is no dividend forecast, and share issuance reflects capital increases due to stock option exercises and a capital reduction. No forward-looking guidance has been disclosed.
Key Figures
- Revenue: 503,090千円（前年同期 28,546千円）
- Operating loss: △767,606千円（前年同期 △1,267,127千円）
- Interim net loss: △762,153千円（前年同期 △1,313,230千円）
AI要約
Performance overview
Oncolys Biopharma's FY2026 interim second quarter results show revenue of 503,090 thousand yen, with operating loss, ordinary loss, and interim net loss all in the red. Revenue grew notably versus the same period last year, and the extent of losses narrowed. However, the financial summary does not disclose forecasts, and earnings guidance is not yet public. In regulatory matters, OBP-301 price approval and price listing are planned, with preparations for product launch underway.
Capital and financial highlights
At interim period end, equity ratio stood at 72.1%, total assets 4,510,606 thousand yen. Paid-in capital and capital surplus were reduced to reflect the exercise of stock acquisition rights and a capital reduction as of May 31, 2026, with remaining earnings carried forward. Outstanding shares were 29,319,700, with a period-average of 29,284,197. Cash flows: operating activities △1,017,309 thousand yen, investing activities △31,525 thousand yen, financing activities +496,622 thousand yen, ending cash and cash equivalents of 2,941,682 thousand yen.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
